DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Saturday morning. The firm issued a hold rating on the stock.

A number of other research analysts have also issued reports on DBVT. HC Wainwright boosted their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Price Performance

NASDAQ DBVT opened at $4.52 on Friday. The company has a market cap of $92.98 million, a P/E ratio of -1.00 and a beta of 0.64. The stock has a 50-day moving average of $3.56 and a two-hundred day moving average of $3.86. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.49.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $1.10. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.17 million. On average, analysts anticipate that DBV Technologies will post -7.05 EPS for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.